# A Study of Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. (TALISMAN)

> **NCT01204697** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 74 (actual)

## Conditions studied

- Non-Squamous Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** docetaxel
- **DRUG:** erlotinib [Tarceva]
- **DRUG:** erlotinib [Tarceva]

## Key facts

- **NCT ID:** NCT01204697
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2015-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01204697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01204697, "A Study of Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. (TALISMAN)". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01204697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*